We are developing a new prognostic biomarker as a companion diagnostic (CDx) that can determine which patients should receive anti-EGF therapy in metastatic colorectal cancer (mCRC).

    Currently, all mCRC patients are routinely tested for presence of KRAS mutations, and only those patients with wild type KRAS gene are indicated to receive anti-EGFR therapy.

    A new diagnostic biomarker for colorectal cancer (CRC) to improve patient stratification before molecular (anti-EGFR) therapy.